Carlyle Group Inc. Amends QuidelOrtho Stake Filing
Ticker: CGABL · Form: SC 13D/A · Filed: Aug 5, 2024 · CIK: 1527166
| Field | Detail |
|---|---|
| Company | Carlyle Group Inc. (CGABL) |
| Form Type | SC 13D/A |
| Filed Date | Aug 5, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 10 min |
| Key Dollar Amounts | $0.001, $38.88, $40.09, $39.7442, $38.25 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 13d-amendment, shareholder-activity
Related Tickers: QDEL
TL;DR
Carlyle Group filed an update on their QuidelOrtho stake. Check the details.
AI Summary
Carlyle Group Inc. filed an amendment to its Schedule 13D on August 5, 2024, regarding its beneficial ownership of QuidelOrtho Corp. The filing indicates a change in the reporting person's holdings, but specific details on the exact percentage or number of shares changed are not immediately available in this excerpt. The filing is an amendment, suggesting an update to previously disclosed information about Carlyle's stake in QuidelOrtho.
Why It Matters
This filing signals a potential shift in a major shareholder's position in QuidelOrtho, which could influence market perception and stock price.
Risk Assessment
Risk Level: medium — Amendments to 13D filings can indicate significant changes in a major shareholder's intentions or holdings, potentially impacting the stock.
Key Players & Entities
- Carlyle Group Inc. (company) — Filing entity
- QuidelOrtho Corp (company) — Subject company
- CARLYLE HOLDINGS II GP L.L.C. (company) — Group member
- CARLYLE HOLDINGS II L.L.C. (company) — Group member
- CARLYLE PARTNERS VI CAYMAN HOLDINGS, L.P. (company) — Group member
- CG SUBSIDIARY HOLDINGS L.L.C. (company) — Group member
- TC GROUP CAYMAN INVESTMENT HOLDINGS SUB L.P. (company) — Group member
- TC GROUP CAYMAN INVESTMENT HOLDINGS, L.P. (company) — Group member
- TC GROUP VI CAYMAN, L.L.C. (company) — Group member
- TC GROUP VI CAYMAN, L.P. (company) — Group member
FAQ
What specific changes are reported in this SC 13D/A filing by Carlyle Group Inc. regarding QuidelOrtho Corp?
The filing is an amendment to a Schedule 13D, indicating a change in reporting status or holdings, but the specific details of the change (e.g., number of shares, percentage) are not provided in this excerpt.
When was this SC 13D/A filing submitted by Carlyle Group Inc.?
The filing was submitted on August 5, 2024.
What is the subject company of this filing?
The subject company is QuidelOrtho Corp.
What is the primary business of QuidelOrtho Corp?
QuidelOrtho Corp is involved in In Vitro & In Vivo Diagnostic Substances, with SIC code 2835.
What is the business address of Carlyle Group Inc. as listed in the filing?
The business address for Carlyle Group Inc. is C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON, DC 20004.
Filing Stats: 2,456 words · 10 min read · ~8 pages · Grade level 8.2 · Accepted 2024-08-05 16:30:31
Key Financial Figures
- $0.001 — relating to the common stock, par value $0.001 per share (the “Common Stock&rdqu
- $38.88 — e Per Share July 30, 2024 150,590 $38.88 to $40.09 $39.7442 July 31, 2024
- $40.09 — e July 30, 2024 150,590 $38.88 to $40.09 $39.7442 July 31, 2024 164,877
- $39.7442 — 30, 2024 150,590 $38.88 to $40.09 $39.7442 July 31, 2024 164,877 $38.25 to $
- $38.25 — $39.7442 July 31, 2024 164,877 $38.25 to $39.80 $39.1065 August 1, 2024
- $39.80 — 2 July 31, 2024 164,877 $38.25 to $39.80 $39.1065 August 1, 2024 234,935
- $39.1065 — 31, 2024 164,877 $38.25 to $39.80 $39.1065 August 1, 2024 234,935 $39.83 to
- $39.83 — $39.1065 August 1, 2024 234,935 $39.83 to $42.52 $41.5156 August 2, 2024
- $42.52 — August 1, 2024 234,935 $39.83 to $42.52 $41.5156 August 2, 2024 169,467
- $41.5156 — 1, 2024 234,935 $39.83 to $42.52 $41.5156 August 2, 2024 169,467 $39.96 to
- $39.96 — $41.5156 August 2, 2024 169,467 $39.96 to $43.0003 $42.1015 (d) None. (e
- $43.0003 — August 2, 2024 169,467 $39.96 to $43.0003 $42.1015 (d) None. (e) Not appli
- $42.1015 — , 2024 169,467 $39.96 to $43.0003 $42.1015 (d) None. (e) Not applicable. CU
Filing Documents
- formsc13da.htm (SC 13D/A) — 272KB
- 0001493152-24-030259.txt ( ) — 274KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : August 5, 2024 The Carlyle Group Inc. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings II GP L.L.C. By: The Carlyle Group Inc., its sole member By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Chief Financial Officer Carlyle Holdings II L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director CG Subsidiary Holdings L.L.C. By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group Cayman Investment Holdings, L.P. By: CG Subsidiary Holdings L.L.C., its general partner By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group Cayman Investment Holdings Sub L.P. By: TC Group Cayman Investment Holdings, L.P., its general partner By: CG Subsidiary Holdings L.L.C., its general partner By: /s/ Anne Frederick, attorney-in-fact Name: John C. Redett Title: Managing Director TC Group VI Cayman, L.L.C. By: /s/ Robert Rosen Name: Robert Rosen Title: Vice President TC Group VI Cayman, L.P. By: TC Group VI Cayman, L.L.C., its general partner By: /s/ Robert Rosen Name: Robert Rosen Title: Vice President Carlyle Partners VI Cayman Holdings, L.P. By: TC Group VI Cayman, L.P., its general partner By: TC Group VI Cayman, L.L.C., its general partner By: /s/ Robert Rosen Name: Robert Rosen Title: Vice President